Paper Details

  1. Home
  2. Paper Details

Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial).

Author: ColletteLaurence, De PrijckLinda, FossaSophie D, HoekstraWytse, KarthausPeter P, KurthKarl-Heinz, SchröderFritz H

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized controlled trial evaluated the effect of early versus delayed endocrine treatment (ET) in 234 patients with lymph node-positive prostate cancer (PCa). Patients received either immediate or delayed ET without treatment of the primary tumor. After 13 years of follow-up, survival and PCa-specific survival were similar between groups, but the trial was underpowered to show non-inferiority.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The timing of endocrine treatment (ET) for prostate cancer (PCa) remains controversial. The issue is addressed in European Organisation for the Research and Treatment of Cancer (EORTC) protocol 30846 for patients with lymph node-positive (pN1-3) cancer without local treatment of the prim...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.eururo.2008.09.008

データ提供：米国国立医学図書館（NLM）

The Timing Game: Evaluating Early vs. Delayed Endocrine Treatment for Prostate Cancer

The world of prostate cancer (PCa) is a vast and complex desert, where researchers are constantly seeking the most effective strategies for treating this disease. This study delves into the timing of endocrine treatment (ET), a crucial aspect of PCa management. The researchers aimed to compare the outcomes of immediate ET versus delayed ET in patients with lymph node-positive PCa who did not receive local treatment of the primary tumor. Their findings suggest that the timing of ET may not significantly impact overall survival in this specific patient population, providing valuable insights for clinicians in making treatment decisions.

A Shifting Sands: No Significant Difference in Survival Outcomes

The study found no statistically significant difference in overall survival between the immediate and delayed ET groups. This finding suggests that the timing of ET may not be a critical factor in determining survival outcomes in this specific patient population. While the study was underpowered to prove non-inferiority, the results provide valuable data for clinicians in making informed treatment decisions.

A Navigating the Desert: Considerations for Treatment Decisions

This study underscores the importance of careful consideration in determining the optimal treatment approach for PCa. While the timing of ET may not significantly impact overall survival in this specific patient population, other factors such as disease stage, patient preferences, and potential side effects should be carefully weighed. This study provides valuable information for clinicians and patients in navigating the complex world of PCa treatment.

Dr.Camel's Conclusion

This study takes us on a journey through the shifting sands of prostate cancer treatment. While it suggests that the timing of endocrine treatment may not have a significant impact on survival in this particular patient population, it underscores the importance of individualized care and careful consideration of all factors when making treatment decisions.

Date :
  1. Date Completed 2014-09-11
  2. Date Revised 2009-12-09
Further Info :

Pubmed ID

18823693

DOI: Digital Object Identifier

10.1016/j.eururo.2008.09.008

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.